Tumor-specific urinary matrix metalloproteinase fingerprinting: Identification of high molecular weight urinary matrix metalloproteinase species

Clinical Cancer Research

Volumn 14, Issue 20, 2008, Pages 6610-6617

  Roy, Roopali ^a,d   Louis, Gwendolyn ^a,d   Loughlin, Kevin R ^b,d   Wiederschain, Dmitri ^a   Kilroy, Susan M ^a   Lamb, Carolyn C ^c,d   Zurakowski, David ^a,d   Moses, Marsha A ^a,d  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; PROTEIN ADAMTS 7; UNCLASSIFIED DRUG; ADAM PROTEIN; ADAMTS7 PROTEIN, HUMAN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR MARKER;

ARTICLE; BLADDER CARCINOMA; CHROMATOGRAPHY; CONTROLLED STUDY; DNA FINGERPRINTING; ENZYME ACTIVITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; URINALYSIS; ZYMOGRAPHY; BLADDER TUMOR; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; DIMERIZATION; ENZYMOLOGY; IMMUNOPRECIPITATION; PROGNOSIS; PROSTATE TUMOR; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; URINE;

ADAM PROTEINS; CASE-CONTROL STUDIES; DIMERIZATION; HUMANS; IMMUNOPRECIPITATION; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MOLECULAR WEIGHT; NEOPLASM STAGING; PROGNOSIS; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 58049203639     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1136     Document Type: Article

References (45)

1. Roy R, Zhang B, Moses MA. Making the cut: protease-mediated regulation of angiogenesis. Exp Cell Res 2006;312:608-22.
2. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89:1260-70.
3. Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999;43 Suppl:S42-51.
4. Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 1999;189:300-8.
5. Nagase H, Woessner JF, Jr. Matrix metalloproteinases. J Biol Chem 1999;274:21491-4.
6. Fang J, Shing Y, Wiederschain D, et al. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor mode. Proc Nat Acad Sci USA 2000;97:3884-9.
7. Bergers G, Brekken R, McMahon G, et al. Matrix met-alloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737-44.
8. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nature reviews 2002;2:161-74.
9. Bode W. Structural basis of matrix metalloproteinase function. Biochem Soc Symp 2003;70:1-14.
10. Garbisa S, Scagliotti G, Masiero L, et al. Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res 1992;52:4548-9.
11. Nakajima M, Welch DR, Wynn DM, TsuruoT, Nicolson GL. Serum and plasma M(r) 92,000 progelatinase levels correlate with spontaneous metastasis of rat 13762NF mammary adenocarcinoma. Cancer Res 1993;53:5802-7.
12. Gohji K, Fujimoto N, Komiyama T, et al. Elevationof serum levels of matrix metalloproteinase-2 and-3 as new predictors of recurrence in patients with urothelial carcinoma. Cancer1996;78:2379-87.
13. Guan KP, Ye HY, Yan Z,Wang Y, Hou SK. Serum levels of endostatin and matrix metalloproteinase-9 associated with high stage and grade primary transitional cell carcinoma of the bladder. Urology 2003;61:719-23.
14. Vasala K, Turpeenniemi-Hujanen T. Serum tissue inhibitor of metalloproteinase-2 (TIMP-2) and matrix metalloproteinase-2 in complex with the inhibitor (MMP-2:TIMP-2) as prognostic markers in bladder cancer. Clin Biochem 2007;40:640-4.
15. Wu ZS, Wu Q, Yang JH, et al. Prognostic significance of MMP-9 andTIMP-1 serum and tissue expression in breast cancer. Int J Cancer 2008;122:2050-6.
16. Davies B, Waxman J, Wasan H, et al. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res 1993;53:5365-9.
17. Jung K, Krell HW, Ortel B, et al. Plasma matrix metal- loproteinase 9 as biomarker of prostate cancer progression in Dunning (Copenhagen) rats. Prostate 2003;54:206-11.
18. Moses MA,Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC, Freeman MR. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res 1998;58:1395-9.
19. Yan L, Borregaard N, Kjeldsen L, Moses MA. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem 2001;276:37258-65.
20. Fernandez CA,Yan L, Louis G,Yang J, Kutok JL, Moses MA. The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res 2005;11:5390-5.
21. Smith E, Zurakowski D, Saad A, Scott RM, Moses MA. Urinary biomarkers predict brain tumor presence and response to therapy. Clin Cancer Res 2008;14:2378-86.
22. Smith ER, Manfredi M, Scott RM, Black PM, Moses MA. A recurrent craniopharyngioma illustrates the potential usefulness of urinary matrix metalloproteinases as noninvasive biomarkers: case report. Neurosurgery 2007;60:E1148-9;discussion E9.
23. Sier CF, Casetta G,Verheijen JH, et al. Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers. Clin Cancer Res 2000;6:2333-40.
24. Monier F, Surla A, Guillot M, Morel F. Gelatinase isoforms in urine from bladder cancer pzatients. Clin Chim Acta 2000;299:11-23.
25. Gerhards S, Jung K, Koenig F, et al. Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma. Urology2001;57:675-9.
26. Durkan GC, Nutt JE, Rajjayabun PH, Neal DE, Lunec J, Mellon JK. Prognostic significance of matrix metal-loproteinase-1 and tissue inhibitor of metalloprotei-nase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder. Clin Cancer Res 2001;7:3450-6.
27. Monier F, Mollier S, Guillot M, Rambeaud JJ, Morel F, Zaoui P. Urinary release of 72 and 92 kDa gelatinases, TIMPs, N-GAL and conventional prognostic factors in urothelial carcinomas. Eur Urol 2002;42:356-63.
28. Eissa S, Swellam M, el-Mosallamy H, et al. Diagnostic value of urinary molecular markers in bladder cancer. Anticancer Res 2003;23:4347-55.
29. Nutt JE, Durkan GC, Mellon JK, Lunec J. Matrix metalloproteinases (MMPs) in bladder cancer: the induction of MMP9 by epidermal growth factor and its detection in urine. BJU Int 2003;91:99-104.
30. Saito M, Kimoto M, Araki T, et al. Proteomeanalysis of gelatin-bound urinary proteins from patients with bladder cancers. Eur Urol 2005;48:865-71.
31. Roy R,Wewer UM, Zurakowski D, Pories SE, Moses MA. ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J Biol Chem 2004;279:51323-30.
32. MacCoss MJ, Wu CC, Yates JR III. Probability-based validation of protein identifications using a modified SEQUES Talgorithm. Anal Chem 2002;74:5593-9.
33. Jaeschke R, Guyatt GH, Sackett DL. Users' guides to the medical literature. III. How to use an article about a diagnostic test. B.What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. JAMA 1994;271: 703-7.
34. Chatterjee S, Price B. Regression analysis by example. 4th ed. New York: John Wiley;2006. p. 317-40.
35. Goldberg GI, Strongin A, Collier IE, Genrich LT, Marmer BL. Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem 1992;267:4583-91.
36. Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 1993;268:10425-32.
37. Toth M, Gervasi DC, Fridman R. Phorbol ester-induced cell surface association of matrix metalloprotei-nase-9 in human MCF10A breast epithelial cells. Cancer Res 1997;57:3159-67.
38. Vartio T, Baumann M. Human gelatinase/type IV procollagenase is a regular plasma component. FEBS Lett 1989;255:285-9.
39. Olson MW, Bernardo MM, Pietila M, et al. Characterization of the monomeric and dimeric forms of latent and active matrix metalloproteinase-9. Differential rates for activation by stromelysin 1. J Biol Chem 2000;275:2661-8.
40. Jinga DC, Blidaru A, Condrea I, et al. MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factors. J Cell Mol Med 2006;10:499-510.
41. Seo YS, Park JJ, Kim JH, et al. Usefulness of MMP-9/TIMP-1 in predicting tumor recurrence in patients undergoing curative surgical resection for gastric car-cinoma.Dig Dis Sci 2007;52:753-9.
42. Morgia G, Falsaperla M, Malaponte G, et al. Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. Neurol Res 2005;33:44-50.
43. Lebensztejn DM, Sobaniec-Lotowska ME, Bauer M, Kaczmarski M, Voelker M, Schuppan D. Serum fibrosis markers as predictors of an antifibrotic effect of interferon alfa in children with chronic hepatitis B. Eur J Gastroenterol Hepatol 2005;17: 843-8.
44. Apte SS. A disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type1 motifs: the ADAMTS family. Int J Biochem Cell Biol 2004;36: 981-5.
45. Liu CJ, Kong W, Ilalov K, et al. ADAMTS-7: a metal-loproteinase that directly binds to and degrades cartilage oligomeric matrix protein. FASEB J 2006;20:988-90.